Are calcineurin inhibitors-free regimens ready for prime time

Kidney International

Volumn 82, Issue 10, 2012, Pages 1054-1060

  Vincenti, Flavio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

immunosuppression; nephrotoxicity; transplantation

Indexed keywords

ABATACEPT; ASKP 1240; BELATACEPT; CALCINEURIN INHIBITOR; CD40 LIGAND; CYCLOSPORIN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; TOFACITINIB; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC DRUG ADMINISTRATION; DRUG APPROVAL; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; IMMUNOREACTIVITY; INFECTION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SHORT COURSE THERAPY; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; THROMBOEMBOLISM;

CALCINEURIN; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; PIPERIDINES; PYRIMIDINES; PYRROLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84868574018     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.194     Document Type: Short Survey

References (42)

1. Kaplan B, Meier-Kriesche HU. Renal transplantation: a half century of success and the long road ahead. J Am Soc Nephrol 2004; 15: 3270-3271. (Pubitemid 39578861)
2. McCullough KP, Keith DS, Meyer KH et al. Kidney and pancreas transplantation in the United States, 1998-2007: access for patients with diabetes and end-stage renal disease. Am J Transplant 2009; 9(Part 2): 894-906.
3. Meier-Kriesche HU, Schold JD, Srinivas TR et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383. (Pubitemid 38282293)
4. Lamb KE, Lodhi S, Meier-Krieshe H-U. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450-462.
5. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729 (Pubitemid 39665325)
6. Opelz G, Döhler B. Collaborative Transplant Study. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009; 87: 795-802.
7. Nankivell BJ, Borrows RJ, Fung CL et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565. (Pubitemid 39097102)
8. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003; 349: 931-940. (Pubitemid 37064766)
9. Gaston RS, Cecka JM, Kasiske BL et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
10. Park WD, Griffin MD, Cornell LD et al. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987-1997.
11. Snanoudj R, Royal V, Elie C et al. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under lowdose cyclosporine therapy. Am J Transplant 2011; 11: 2635-2646.
12. Ekberg H, Bernasconi C, Tedesco-Silva H et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876-1885.
13. Vincenti F. Immunosuppression minimization: current and future trends in transplant immunosuppression. J Am Soc Nephrol 2003; 14: 1940-1948. (Pubitemid 36750490)
14. Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001; 71: 1282-1287. (Pubitemid 32507148)
15. Flechner SM, Glyda M, Cockfield S et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633-1644.
16. Schena FP, Pascoe MD, Alberu J et al. Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
17. Flechner SM, Goldfarb D, Modin C et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
18. Vincenti F, Charpentier B, Vanrenterghem Y et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
19. Durrbach A, Pestana JM, Pearson T et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-557.
20. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-453. (Pubitemid 40313335)
21. Vincenti F, Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med 2007; 58: 347-358. (Pubitemid 46706519)
22. Vincenti F, Larsen C, Durrbach A et al. Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Eng J Med 2005; 353: 770-781. (Pubitemid 41215486)
23. Vincenti F, Larsen CP, Alberu J et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210-217.
24. Pestana JO, Grinyo JM, Vanrenterghem Y et al. Three-year outcomes from BENEFITEXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630-639.
25. Goldfarb DA, Matin SF, Braun WE et al. Renal outcome 25 years after donor nephrectomy. J Urology 2001; 166: 2043-2047. (Pubitemid 33065212)
26. Vincenti F, Amend WJ, Kaysen G et al. Long-term renal function in kidney donors. Sustained compensatory hyperfiltration with no adverse effects. Transplantation 1983; 36: 626-629. (Pubitemid 14216269)
27. Sellarés J, de Freitas DG, Mengel M et al. Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. Am J Transplant 2011; 11: 489-499.
28. Everly MJ, Everly JJ, Arend LJ et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063-1071.
29. Terasaki P, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005; 80: 1194-1197. (Pubitemid 41746796)
30. Larsen CP, Knechtle SJ, Adams A et al. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6: 876-883. (Pubitemid 44356637)
31. Klintmalm GB, Feng S, Lake JR et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II study. Am J Transplant 2011; 11(Suppl 2): 137 (abstract no. 355).
32. Hagerty H. Belatacept 6-month intravenous toxicity study in monkeys. Transplant Int 2011; 24: 257.
33. Vincenti F, Schena FP, Parakevas S et al. FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307-316.
34. Woodle ES, First MR, Pirsch J et al. A prospective, randomized, doubleblind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577.
35. Ferguson R, Grinyó J, Vincenti F et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011; 11: 56-76.
36. Vincenti F, Klintmalm G, Halloran PF. Open letter to the FDA: new drug trials must be relevant. Am J Transplant 2008; 8: 733-734. (Pubitemid 351347744)
37. Kirk AD, Burkly LC, Batty DS et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686.
38. Vincenti F, Kirk A. What's next in the pipeline. Am J Transplant 2009; 8: 1972-1981.
39. Goldwater R, Keirns J, Blahunka P et al. A phase I single ascending dose study of ASKP1240 (Anti-CD40 MAB) in healthy subjects. Am J Transplant 2011; 11(Suppl 2): 127 (abstract no. 321).
40. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
41. Kirk AD, Harlan DM, Armstrong NN et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789.
42. Vincenti F, Silva HT, Busque S et al. Efficacy and safety of CP-690,550-MPA combination regimens in de novo kidney transplant patients: 12-month final results of a phase 2b study. Am J Transplant 2012 (in press).